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Abstract: Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and 
peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory 
and pathological findings.  
Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the 
adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demye-
linating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The pos-
sibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strate-
gies for neurorehabilitation, neuroregeneration, and neurorepair.  
This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing 
on epidemiology, clinical aspects and treatments. 
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-
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INTRODUCTION 
  Inflammatory demyelinating diseases comprise a spec-
trum of disorders affecting the myelin of central (CNS) and 
peripheral nervous system (PNS). These disorders can   
usually be differentiated on the basis of clinical, imaging, 
laboratory and pathological findings [1].  
  Demyelination is often secondary to an infectious, 
ischemic, metabolic, or hereditary disorder. The cause of 
primary demyelinating disorders is unknown, but autoim-
mune mechanisms are suspected [2]. The concept of primary 
demyelination implies the destruction of myelin sheets,   
oligodendrocytes, and Schwann cells with relative preserva-
tion of other nervous system components. However, axonal 
injury is a common finding in demyelinating lesions, which 
well correlates with permanent functional deficits [3]. 
  Some myelin disorders tend to affect primarily the mye-
lin of peripheral nerves, while others affect the CNS. In most 
individuals, demyelinating diseases are restricted to one or 
the other compartment but patients with concomitant CNS 
and PNS inflammatory demyelinating processes have been 
reported [4, 5]. 
  Idiopathic inflammatory-demyelinating diseases (IIDDs) 
constitute a heterogeneous group of CNS disorders thought  
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to be of autoimmune origin and including acute disseminated 
encephalomyelitis, multiple sclerosis, Devic’s disease, trans-
verse myelitis, and clinically isolated syndromes such as 
optic neuritis. This spectrum includes monophasic, multipha-
sic, and progressive disorders ranging from highly localized 
forms to multifocal or diffuse variants (Table 1) [6, 7].  
  Acquired inflammatory demyelination of the peripheral 
nervous system also may have autoimmune origin and   
can present acutely as the heterogeneous entity known as 
Guillain-Barre´ syndrome (GBS) or in a more protracted, 
sometimes relapsing course, known as chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) (Table 2) [5].  
  Recent studies have contributed to current awareness that 
these disorders are not restricted to the adult age group, but 
are more common in the pediatric age then hitherto believed. 
Some of pediatric inflammatory demyelinating diseases 
carry an unfavorable long-term prognosis but timely and 
tailored treatments can improve the outcome. The possibility 
of physical and cognitive disability resulting from these dis-
eases, highlights the urgent need for therapeutic strategies for 
neurorehabilitation, neuroregeneration, and neurorepair [3]. 
The therapeutic strategy is actually in progress. Actually it is 
defined that acute demyelination in children is managed in 
the same way as adult patients, while DMTs have not been 
approved by FDA for treatment of pediatric demyelinating 
diseases [8, 9]. However, encouraging data regarding safety 
and efficacy of first-line therapies come out from the few 
study on pediatric population. 136    Current Neuropharmacology, 2010, Vol. 8, No. 2  Spalice et al. 
Table 1.  Classification of the Idiopathic Inflammatory   
Demyelinating Disease of CNS 
Idiopathic Inflammatory Demyelinating Disease of CNS 
Monofocal forms 
Acute hemorrhagic leukoencephalitis 
Optic neuritis 
Spinal Cord lesions: 
- acute necrotizing myelitis 
- transverse myelitis 
Pontine and extrapontine myelinolysis 
Multifocal forms 
Multiple sclerosis 
Acute disseminated encephalomyelitis 
Neuromyelitis optica or Devic’s syndrome 
Forms with sclerosis 
Baló’s concentric sclerosis 
Schilder’s disease 
 
Table  2.  Classification of the Idiopathic Inflammatory   
Neuropathies 
Idiopathic Inflammatory Neuropathy 
Acute 
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) 
Acute motor axonal neuropathy (AMAN) 
Acute motor-sensory axonal neuropathy (AMSAN) 
Fisher Syndrome and other regional variants 
Pharyngeal-cervical-brachial 
Paraparetic 
Facial palsies 
Pure oculomotor 
Functional variants of Guillain-Barre´ syndrome 
Pure dysautonomia 
Pure sensory Guillain-Barre´ syndrome 
Ataxic Guillain-Barre´ syndrome 
Subacute 
Subacute inflammatory demyelinating polyradiculoneuropathy 
Chronic 
Chronic inflammatory demyelinating polyradiculoneuropathy 
Multifocal motor neuropathy with conduction block 
Chronic relapsing axonal neuropathy 
Chronic ataxic sensory neuronopathy 
  This review discusses characteristics of primary demyeli-
nating disease more frequently observed in childhood, focus-
ing on epidemiology, clinical aspects and treatments. 
MULTIPLE SCLEROSIS 
  Multiple Sclerosis (MS), the prototype of the autoim-
mune inflammatory diseases of the CNS, is characterized by 
both axonal damage and diffuse areas of inflammatory non-
vasculitic demyelination involving the encephalic and spinal 
white matter [10].  
  To date, the pathogenesis of MS is not completely ex-
plained and, as the other autoimmune diseases, it is consid-
ered to be a complex interplay of immune system reactivity 
and environmental triggers (e.g., viruses) associated with a 
background of genetic susceptibility resulting in an immune-
mediated demyelination, axonal loss, and neurodegeneration. 
Putative environmental triggers, such as vitamin D homeo-
stasis, early dietary exposures, seasonality of birth, and the 
timing and sequence of viral exposures during childhood are 
being explored [8].  
  MS primarily affects young adults, with a peak of inci-
dence between the ages of 20 and 40, and is the main cause 
of non-traumatic neurological disability in the industrialized 
world [11]. However, it is estimated that, in approximately 
1% of cases, the onset of MS (defined by the presence of the 
first neurological symptom) is before 10 years (very early 
onset multiple sclerosis, VEOMS) and up to 3-5% between 
11-16 years (early onset multiple sclerosis, EOMS) [12, 13]. 
The term “Pediatric MS” refers to the first clinical demyeli-
nation episode before the age of 18. 
  The female preponderance observed in adult-MS is also 
notable in pediatric-MS, but the female:male ratio in patients 
with pediatric-MS is approximately equal. A family history 
of MS is present in 6-8% of children with MS [14]. 
  The diagnosis of MS in pediatric age is not easy to 
achieve because of difficulties for clinicians in recognizing 
the patients that do not fit the typical age range of 20-40 
years [15]. In addition, the trouble of the differential diagno-
sis is linked to other inconveniences such as the many types 
of primary or secondary CNS disorders resembling demyeli-
nating diseases, or the atypical presentation of clinical (fever, 
involvement of peripheral nervous system, encephalopathy, 
absence of attacks symptoms, progressive course), laboratory 
[absence of cerebrospinal fluid (CSF) oligoclonal IgG, CSF 
pleocytosis, elevation of leukocyte count or erythrocyte 
sedimentation rate], neuroimaging findings [16, 17]. Thus, 
MS is probably underdiagnosed in the pediatric population 
[11].  
  Among the numerous groups of diseases that may lead a 
misdiagnosis of MS we distinguish infections (neuroborreli-
osis, neuro-AIDS, neurosyphilis, subacute sclerosing panen-
cephalitis, parasites, progressive multifocal leukoencephalo-
pathy, Human T-cell lymphotropic virus), neoplasms (astro-
cyroma, lymphoma), inflammatory diseases (systemic lupus 
erythematosus, Bechet disease, neurosarcoidosis, Sjogren 
disease), leukoencephalopathies (adrenoleukodystophy, 
metachromatic leukodystrophy, Krabbe disease, Pelizaeus-
Merzbacher disease, Refsum disease, MELAS, MERFF, 
Wilson disease, Alexander disease, Fabry disease, Leigh 
disease, Kearns-Sayre syndrome), vitamin deficiencies (B12 
or E or folate deficit), gastrointestinal disease (Whipple dis-Treatment of Pediatric Demyelinating Diseases  Current Neuropharmacology, 2010, Vol. 8, No. 2    137 
ease, celiac disease), vascular disorders (moya-moya disease, 
CADASIL, vasculitis), and other disorders [17]. 
  In order to improve our understandings on pediatric de-
myelinating diseases and to better characterized the clinical 
features [18], the differential diagnosis [17] and optimal 
therapy [9] for these disorders, the International Pediatric 
MS Study Group developed consensus definitions regarding 
the major CNS inflammatory demyelinating disorders of 
children and adolescents [19].  
  As for adult patients, the diagnosis of pediatric MS re-
quires dissemination in space and time, involving the neces-
sity of, at least, a second episode before establishing it. The 
space involvement could be evaluated by means of both a 
history and neurological findings consistent with a multifocal 
disease, and neuroimaging techniques [11]. The MRI is used 
in the first three months after the initial clinical attack (also 
called Clinically Isolated Syndrome), and it is considered 
positive if three of the following four features are satisfied 
[20]: 1) nine or more white matter lesions or one gadolinium 
enhancing lesion, 2) three or more periventricular lesions, 3) 
one juxtacortical lesion, 4) an infratentorial lesion [19]. Two 
MRI lesions, with one in the brain, are sufficient for meeting 
dissemination in space criteria if associated with abnormal 
(CSF) (e.g. oligoclonal band or elevated IgG index) [19]. 
However, at present, there are four proposed MRI diagnostic 
criteria for pediatric MS needing for validity [20-23]. 
  Finally, the ADEM diagnostic criteria should not be 
achieved (see ADEM section for ADEM diagnostic criteria 
and for comparison with MS) [19]. If first episode is ADEM, 
two or more non-ADEM events are required for diagnosis of 
MS. New MRI lesions 3 months or longer after the initial 
clinical event can be used to satisfy criteria for dissemination 
in time [19].  
  The main clinical features of MS encompass visual, sen-
sory, motor and cognitive functions, although every neuro-
logical functions may be involved in connection with site 
and/or size of the active demyelinating lesions (e.g. lesions 
bigger than or equal to 2 cm have been renamed “tumefac-
tive demyelinating lesions” (Fig. 1) and may be clinically 
devastating [24], with encephalopathy and seizures). Pediat-
ric patients typically have a polysymptomatic onset, although 
monosymptomatic presentations are not uncommon [25].  
  The natural history of MS is variable, and 4 different sub-
types have been recognized on the basis of the clinical 
course in pediatric population: Relapsing-Remitting (RR) 
form, occurring for 90% of cases, is characterized by periods 
of neurological dysfunctions followed by clinical improve-
ment (partial or complete) and spaced out by clinical stabil-
ity; the remaining patients could experience Primary-
Progressive form (PP; 2.3-7% of cases), Secondary-
Progressive (SP) form (as evolution of a RR form, conse-
quence of a progressive neurological function deterioration, 
even in the absence of acute events [26]), Progressive-
Relapsing (PR) form [18]. In the initial stages, pediatric MS 
is considered to have a more favorable prognosis compared 
to adult MS; however, over the long term, pediatric MS   
patients can become disabled at younger age owing to   
the periodic demyelinating episodes, indicating that MS in 
pediatric population does not have a benign outcome [18]. 
Consequently, a well-timed and correct diagnosis of early 
MS is pivotal for starting the appropriate treatment and man-
agement [9]. It should be kept on mind that adolescents with 
MS have an increased risk of depression, mood-swings and 
behavioral problems, that could be raised by the disease 
course, the onset of disability, the use of disease-modifying 
therapies [27]; thus, the management should be multidisci-
plinary, involving neurologist and psychologist or psychia-
trist [25].  
 
 
 
 
 
 
 
 
 
 
Fig. (1). Axial view T2 weighted. A 12-year-old girl coming to our 
attention for acute right hemiparesis and deficiency of the seventh 
cranial nerve. Multiple lesions in the periventricular white matter 
prevailing on the left side. Diagnosis: tumefactive MS. 
  The management of acute relapses in children generally 
starts with intravenous corticosteroids, at high doses of 20-30 
mg/kg/day (maximum 1 g per day) for 3-5 days, often result-
ing in dramatic clinical improvement [25]. Oral prednisone, 
starting at a dose of 1 mg/kg/day and tapered over 14-21 
days, is administered in cases of incomplete resolution of 
symptoms after intravenous therapy [25].  
  The most frequent side effects of high-doses corticoster-
oids are facial flushing, sleep difficulties, irritability, in-
creased appetite, and, especially in children needing for pro-
longed administration, growth retardation. Side effects such 
as high blood pressure and hyperglycemia are rare in pediat-
ric age, but corticosteroids therapy requires careful monitor-
ing of blood pressure, urine glucose, serum potassium, and 
co-administration of gastric protection. The risk of side ef-
fects is directly proportional to prolonged use and total cu-
mulative dose; reviewed doses are generally well tolerated, 
even when a short oral taper dose is given [9]. 
  Intravenous immunoglobulin (IVIG) (1 g/kg monthly or 
every 3 months, with or without a 5 day induction of 0.4 
g/kg daily, for a total time ranging from 6 to 12 months) or 
plasma-exchange could be used acutely in children who fail 
to respond to corticosteroids [9, 25] or fail, decline, or are 
not able to take standard immunomodulatory therapies [28]. 
The meta-analyses and the several randomized controlled 
trials on adult MS population suggest that IVIG are better 
than placebo in patients with RR-MS, but no trials compar-
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MS patients are available [28]. Furthermore, IVIG in asso-
ciation with high-doses steroids doesn’t seem better than 
steroids alone to treat relapses [9]. IVIG efficacy in pediatric 
population remains unclear [9, 25, 29], and thus, IVIG is not 
recommended for routine treatment of primary or secondary 
progressive MS [28]. However, IVIG could be considered as 
option for treatment of patients with severe, refractory optic 
neuritis which have had no recovery of vision after 3 months 
of standard steroid therapy [28]. The management of relapses 
with plasma-exchange is proposed in adult-MS with severe 
relapses, after the failure of therapy with high-doses steroids; 
thus, plasma-exchange has been suggested in pediatric-MS if 
the gap between acute episodes is too restricted, that hinders 
the high-doses glucosteroids administration and makes easier 
the onset of adverse effects [9]. To date, no studies regarding 
plasma-exchange efficacy and utility in pediatric MS are 
available. 
  In addition to the mentioned options, several disease-
modifying therapies (DMT) are available for pediatric multi-
ple sclerosis: immunomodulatory and immunosuppressive 
drugs belong to these therapies. DMT can reduce the dura-
tion of symptoms or modify the progression of the disease 
[14, 30, 31]. Although open-label studies of DMT such as 
interferon beta-1a [32, 33], interferon beta-1b [31, 34] and 
glatiramer acetate [31, 35] have demonstrated safety and 
efficacy for children, these drugs have not been formally 
approved for pediatric use. There is Class I level of evidence 
for these medications by means of a reduction in frequency 
of clinical relapses (approximately 30%) and reduction in 
disease activity seen on brain MRI. Adverse effects such as 
flu-like symptoms, injection site reaction, elevated liver en-
zymes, or a perceived lack of efficacy by the adolescents 
may result in non-adherence to treatment [27].  
  The starting doses for interferon therapy in pediatric MS 
are object of discussion; however, it is well-know that is 
pivotal to monitoring liver function and white blood cell 
counts monthly; younger children may have a transient ele-
vation in liver transaminases that necessitates a slower esca-
lation to full dose [8]. 
  Glatiramet acetate (GA) and Interferon-beta 1a (IFN-1a) 
and 1b (IFN-1b) belong to the group of immunomodulatory 
therapy approved for adults Relapsing-Remitting MS, on the 
basis of their ability to reduce MRI lesions and relapses rate 
[9]. 
 IFN-1b is a lyophilized protein produced by DNA re-
combinant technology by E. Coli with a wide series of ef-
fects on the immune systems such as inhibition of T-
lymphocyte proliferation and decrease of IFN- production, 
inhibition of major histocompatibility complex class II 
(MHC II) expression, induction of anti-inflammatory and 
inhibition of pro-inflammatory cytokines [36]. It has been 
used in children at the same adult dose (8 Million Interna-
tional Units, MIU) [34]. The most frequent adverse effects 
encompass flu-like manifestations, altered liver function test 
and injection side reaction, without dangerous unforeseeable 
adverse events [34]. However, to date, although IFN-1b 
treatment has very favorable efficacy on clinical and MRI 
measures of disease activity and progression from the very 
early stages of disease, numerous studies on long-term   
efficacy and safety in pediatric ages are not available [9, 31].  
  Interferon beta-1a Intramuscular has been administrated 
in pediatric MS in few studies [32, 37-40] at full doses of 30 
g / week or lower (15 g / week) in children <10 years or 
with a body weight less than 30 kg [25], showing in some 
cases [39] the necessity of treatment interruption for adverse 
effects besides flu-like symptoms, headaches, fever, and   
injection site soreness. However IM IFN-1a seems to be 
effective and well tolerated in pediatric patients with MS 
[32]. 
 IFN-1a could be used subcutaneously at the 1/2 dose of 
22 g times per week (tiw), but a relapse necessitates an in-
crease at the full dose of 44 g three times weekly [9, 33, 
41]. Still for IFNB-1a mild/moderate or severe adverse ef-
fects such as systemic reaction and depression are described 
[33].  
  Glatiramer acetate (GA) is made of a random polypeptide 
(L-glutamic acid, L-lysine, L-alanine, and L-tyrosine), which 
induces an antigenic cross-reactivity with myelin protein 
reactive T cells. GA induces the production of anti-GA-
regulating Th2 T cells that regulate CNS inflammation [11]. 
GA is administered daily as 20 mg subcutaneous injections 
[9], and seems to be well tolerated [37, 42]. Monitoring of 
liver function and hematological parameters is not required 
[8]. 
  The immunosuppressive therapy is generally reserved to 
children with severe course, frequent relapses, progression of 
disability and not responding to first-line treatment, although 
pediatric literature data regarding efficacy and safety are not 
sufficient [3, 8]. Azathioprine, mitoxantrone, cyclophos-
phamide or methotrexate have been used as escalation treat-
ment of pediatric MS, either as monotherapy or as add-on to 
immunomodulation [3]. As well for immunomodulatory me-
dicaments, also the immunosuppressive drugs group has not 
been approved by US Food and Drugs Administration (FDA) 
for MS, with the exception of mitoxantrone for adult patients 
[11]. 
  Azathioprine has been used at oral dose of 1-2 mg/kg/day 
[11] in order to avoid relapses, for patients that do not re-
spond or tolerate immunomodulatory drugs [9, 11]. Disad-
vantageous effects encompass cytopenia, skin rashes, gastro-
intestinal intolerance, abnormal liver toxicity, requiring peri-
odic blood count and liver functions [9, 11]. No certain data 
confirm the risk of secondary cancer after azathioprine use 
[9, 11]. 
  Mitoxantrone is administrated quarterly in adults at doses 
of 12 mg/m
2 IV (maximum cumulative dose of 120 mg/m
2) 
for a full period of 2 years [11], showing good results in 
terms of decreases in progression of disability, relapses   
rate, and onset of new T2 weighted MRI lesions, compared 
with placebo. Cardiotoxicity, leukemia, amenorrhea and   
infection are expected effects. For these reasons, the indica-
tion of mitoxantrone is limited to cases of worsening adult 
MS resistant to other treatments [43]. There is no published 
experience of mitoxantrone in the pediatric MS population 
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  Cyclophosphamide is an alkylating agent used mainly as 
a second-line treatment in multiple sclerosis, and several 
studies have suggested this drug as most beneficial in 
younger adult patients and in patients with early secondary 
progressive MS [11]. Very recently it has been described a 
retrospective study on its use in pediatric series [44]. Cyclo-
phosphamide, administered at 600 to 1, 000 mg/m
2 per dose, 
with the minimum dose required to achieve lymphopenia 
(nadir total white blood cell count less than 3, 000/mm
3 or 
between 1, 500 and 2, 000/mm
3, depending on the institu-
tion) used to guide maintenance therapy, reduces relapses 
rate and stabilizes disability scores in the majority of patients 
[44]. The entire period of therapy could range from few 
months to 3 years, although its use is limited by the onset of 
adverse effects or risk of cystitis and neoplasm [9]. Its effects 
on MRI lesions remains undefined. Infections (especially 
with white blood cells < 1500/mm
3), nausea, transient alope-
cia, gonad failure, hemorrhagic cystitis, bladder and blood 
cancers (particularly if cumulative cyclophosphamide dosage 
is 100 g or more [44]), could derive from treatment with   
cyclophosphamide [9, 11, 44].  
  Methotrexate is rarely used in pediatric MS, and only 
occasionally in progressive forms of MS in adult patients. 
The dosage is 7, 5-20 mg per os once per week, in associa-
tion with folic acid (1 mg/day) to prevent macrocytic ane-
mia. Other major side effects are liver and lung toxicity [9, 
11]. 
  Natalizumab, a humanized monoclonal antibody directed 
against alfa-4 integrins [45] and approved for acute adults 
RR-MS type (300 mg infused monthly) [9], may be another 
medical option in pediatric MS. Recently it has been admin-
istrated at a dosage of 3 to 5 mg/kg of body weight every 4 
weeks in three children with a previous poor response to 
immunomodulatory medicine or with excessive drugs reac-
tion [46]. All these patients had no further relapses, all re-
ported significant improvement in quality of life, and no new 
T2-weighted lesions or gadolinium-enhancing lesions were 
detected at MRI follow-up [46]. Finally no unpredictable 
events were seen when dosage was adjusted to body weight 
[46]. Therefore, it is a promising second-line therapy for 
pediatric patients with RRMS unresponsive to immuno-
modulatory therapy, although not licensed for patients under 
the age of 18 years. 
  In conclusion, to date, the therapeutic strategy of pediat-
ric MS is complicated and variable in relation with the clini-
cal course. The relapse therapy is based primarily on IV cor-
ticosteroids, and, in second instance IVIG or plasma ex-
change. The DMT is approved in case of active RR disease, 
clinically or by MRI defined (more than one clinical relapse 
or new T2 weighted lesions or gadolinium enhancing lesions 
in a period of 1 to 2 years). First line DMT include GA, 
IFNB 1a and 1b, the sole approved by FDA. The drugs 
should be chosen in co-operation with the patient and his 
family after a complete illustration of efficacy, tolerability 
and risks. It has to be kept on mind that clinical, immu-
nologic, pharmacokinetic, and pharmacodynamic responses 
to treatment are different in children versus adults, for exam-
ple in liver and kidney function, fat distribution, gut absorp-
tion, and availability of adequate subcutaneous tissue for 
injection. Thus, the dosage should be adjusted in relation 
with body weight, and, eventually, on the basis of follow-up 
data. The follow-up should include laboratory, MRI scans 
acquisitions, clinical examinations, at a time depending on 
the used drugs. In general, during the first month, liver func-
tion and total blood count should be carefully checked. The 
International Committee suggest that brain MRI scans should 
be acquire 6 to 12 months after starting DMT, and compared 
to the older scans. Neurological examinations should be per-
formed at baseline and then at 1, 3, 6 months, and continued 
every 6 months [19]. After the first year of therapy in stable 
patients without new attacks, clinical and neuroradiological 
follow-up can be performed yearly. In case of first-line 
treatment failure, addition of IV corticosteroids pulse and the 
second-line drugs should be taken into account.  
  A better understanding of the immunologic and patho-
physiological mechanisms underlying multiple sclerosis have 
recently led to the design of numerous novel medical ap-
proaches, based on selective and target-specific therapies 
instead of indiscriminate immunosuppresion or global im-
munomodulation, and trying to protect neurons against ax-
onal damage and loss [47-49]. 
  However, there are unmet needs in MS treatment, such as 
the absence of oral formulations and the adverse side effects 
that mean the partial efficacy, safety and tolerability of ac-
tual DMT [47]. 
ACUTE DISSEMINATE ENCEPHALOMYELITIS 
  Acute disseminate encephalomyelitis (ADEM) is a multi-
focal inflammatory disease of Central Nervous System with 
a benign evolution, usually appearing after an infection or a 
vaccination. ADEM is often characterized by a monophasic 
course with multiple neurological symptoms, including en-
cephalopathy-like syndrome [50-52], which could be absent 
in 0-18% of ADEM patients [8]. Initial symptoms depend on 
the size and the areas involved by the lesions; consequently 
the wide clinical spectrum comprises unilateral or bilateral 
pyramidal signs (60-95%), hemiplegia (76%), ataxia (18-
65%), cranial nerve palsies (22-45%), spinal cord involve-
ment (24%), seizures (13-35%), optic neuritis (7-22%), 
speech alterations (5-21%), hemiparesthesia (2-3%). The 
most of symptoms occur in both adults and children, al-
though some of them seem to be age-related: long-lasting 
fever, headaches and seizures are more frequently observed 
in pediatric patients, while sensory alterations and PNS in-
volvement (acute polyradiculoneuropathy) in adults [53]. 
ADEM pathogenesis is not completely defined; either the 
post-infective or post-vaccinous onset, and the presence of 
autoantibodies against the tetrameric myelin oligodendrocyte 
glycoprotein (MOG), support the hypothesis of inflamma-
tory demyelination triggered by autoimmune mechanisms 
[3]. Although the disease is defined as acute, not necessarily 
all the neurological manifestations have to show themselves 
at the same time; in fact, new symptoms or signs, occurring 
within the first 3 months from the initial episode, are consid-
ered to be part of the same attack [8]. More commonly chil-
dren less then 10 years of age are affected [14], with a mean 
age range of 5-8 years [53]. The gender ratio appears to be 
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relapses can occur, configuring a picture of multiphasic or 
recurrent ADEM. In multiphasic ADEM new clinical attack 
involves CNS areas previously uninjured at least 3 months 
after the first event and at least 1 month after the end of ster-
oids therapy [53]. Differently, the term recurrent ADEM is 
used if the relapse, always arising at least 3 or more months 
after the first event and at least 1 month after the end of ster-
oids therapy, has the same neurological and neuroradiologi-
cal features, suggesting an unmodified involvement of CNS 
areas [53]. However, both in case of multiphasic and recur-
rent type, the ADEM criteria should be met [8]. Actually, 
accurate diagnostic criteria for ADEM are lacking, owing to 
the absence of specific markers [53]. Thus, the main diffi-
culty is the differential diagnosis with pediatric Multiple 
Sclerosis, especially in cases of multiphasic or recurrent 
ADEM, whose correct identification may require a long-term 
follow-up [53]. ADEM diagnostic criteria proposed by an 
International committee include encephalopathy (defined as 
mental status changes and/or behavioral alterations) and 
polysymptomatic presentation as cardinal point for diagnosis 
[19]; MRI and CSF findings, documentation of a prior infec-
tion and clinical evolution could be useful if associated with 
the previous cardinal criteria [19]. 
  Some clinical, neuroradiological and CSF findings could 
be useful in formulating differential diagnosis with MS. For 
example, the ADEM clinical onset is frequently polysymp-
tomatic, with consciousness and behavioral changes (en-
cephalopathy, typically not common in MS), and rarely with 
optic neuritis and sensibility disturbances, typical of MS 
onset [53]. The Magnetic Resonance Imaging, particularly 
T2-weighted and fluid-attenuated inversion recovery 
(FLAIR) sequences, shows lesions of the subcortical, juxta-
cortical and central white matter of hemispheres, cerebellum, 
periventricular zone, brainstem, spinal cord (Fig. 2) [53]. 
The gray matter of thalami and basal ganglia is often af-
fected [53]. The lesions reported above are typically de-
scribed as highly variable in size (more frequently large), 
multiple, bilateral, asymmetric [50, 53]. The gadolinium 
enhanced T1-weighted sequences could show lesions in a 
variable percentage of patients, depending on the inflamma-
tory state [53]. These neuroradiological features of size and 
distribution could be very significant in distinguishing an 
ADEM from MS attack [50]. However, the MRI pattern de-
scribed for ADEM are numerous [54]. Finally, CSF analysis 
could demonstrate an increased number of protein and lym-
phocyte (more then 30 cells/all), although normal values or 
IgG oligoclonal bands may result [50]. There is not a well-
defined standard treatment for ADEM [53]. Treatment of 
demyelinating attacks is based on intravenous corticosteroids 
administration (Methylprednisolone at 10-30 mg/kg/day for 
3-5 days, with a maximum dose of 1 g daily; dexamethasone 
at 1 mg/kg) during acute phase, aiming to reduce the in-
flammatory process. Subsequently, a maintenance steroids 
oral taper, during 4-6 weeks, is pivotal to decreasing the risk 
of recurrence [3]. Better outcome seems to be associated 
with methylprednisolone compared to dexamethasone treat-
ment, although this comparison has been investigated only in 
one study [54], and it has not been confirmed. The adverse 
effects are the same described for high-doses steroids ther-
apy in MS. Intravenous immunoglobulins, at doses of 1-2 
g/kg for a period of 2-5 days, are considered effective and 
recommended in children with persistence of symptoms   
or steroids inefficiency [3]. Not many data are reported in 
literature about plasmapheresis use in ADEM patients, and it 
is considered a rescue treatment after the failure of steroids 
and IGIV, although it seems to be more useful if adminis-
trated in earlier stage of disease [55]. Up to date, DMT are 
not reported to be used in children with ADEM [53]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Axial view T2 weighted: A 7- year-old boy who came to 
our attention because of headache and lethargy following one day 
of fever. Multiple lesions in the left temporo-parietal white matter 
junctions, in the right thalamus and in the pons. Diagnosis: ADEM. 
SCHILDER’S DISEASE 
  Schilder's disease, or myelinoclastic diffuse sclerosis, is a 
rare acute or subacute demyelinating disorder of central 
nervous system affecting children and young patients.  
  In the past this idiopathic inflammatory demyelinating 
disease was considered a subtype of Multiple Sclerosis; 
recent data have demonstrated that this entity presents 
different clinical, radiological, laboratory and pathological 
findings from other demyelinating diseases (Table 3) [6]. 
  In 1912, Schilder first described the disease as 
“encephalitis periaxialis diffusa” and until 1985 the term 
Schilder’s disease was used to describe different demyelina- 
ting disorders of different etiologies, including adrenoleuko- 
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  In 1986, Poser established the diagnostic criteria for non 
invasive diagnosis of Schilder’s disease: clinical symptoms 
and signs often atypical for the early course of MS, CSF 
normal or atypical for MS, large bilateral areas of 
demyelination of cerebral white matter, no fever, no viral or 
mycoplasma infection, nor vaccination preceding the 
neurological symptoms and normal serum concentration of 
very long-chain fatty acids [57]. 
  Pathologically, the disease is characterized by diffuse 
inflammatory demyelination similar to MS, with areas of 
demyelination are grossly more extensive, leading to the 
term “myeloclastic diffuse sclerosis”. The relationship be-
tween Schilder’s disease and MS is unclear, although pa-
tients with Schilder’s disease may develop a relapsing-
remitting courses, typical of MS, and considered by Poser a 
disease “in transition” between Schilder’s disease and MS 
(“transitional sclerosis”). Differences include the apparently 
more severe and often progressive course, and lack of   
pleiocytosis and oligoclonal band in CSF in patients with 
Schilder’s disease. However the distinction between MS and 
Schilder’s disease is probably not so clearly defined [6]. 
  The underlying cause of Schilder's disease is unknown. 
Symptoms are caused by widespread patches of demyelina- 
tion throughout the brain and spinal cord, resulting in 
slowed, faulty nervous transmission. 
  Most patients with Schilder's disease are diagnosed 
between the ages of 5 and 14 years. Patients present with 
gradually more severe symptoms and the disease course can 
include psychiatric predominance, dementia, emiplegia, 
aphasia, ataxia, intracranial hypertension, cortical blindness, 
deafness and other symptoms such as seizures, tremors, poor 
attention, headache, muscle weakness, vomiting, impaired 
vision, personality changes, and difficulty keeping balance 
[58]. Some children have a relentless progressive course, 
culminating in death. Other children may have remissions 
and exacerbations, with each subsequent exacerbation more 
severe and each remission less complete than previous 
episodes, until death supervenes [59, 60]. Schilder's disease 
is uniformly fatal [60, 61]. The prognosis of Schilder’s 
disease is very variable and can take three different courses: 
monophasic not remitting, remitting, and finally, progressive 
with increase in deficits. 
  Imaging studies show large ring-enhancing lesions 
involving both hemispheres, sometimes symmetrically and 
located particularly in the parieto-occipital regions, tipically 
confined to the centrum semiovale [6]. The differential 
diagnosis with brain tumors or abscesses of these large 
demyelinating brain lesions is often difficult, and invasive 
procedures, such as biopsy, are still the gold standard for 
diagnosis [57].  
  Since Schilder's disease is similar to multiple sclerosis, 
treatments for this disease are similar and include high-doses 
steroids, beta interferon, immunosuppressive and sympto- 
matic therapy. The treatment team for children with 
Schilder's disease usually consists of neurologists, specialists 
in multiple sclerosis, and rheumatologists. Support from 
physical therapists, occupational therapists, and speech   
and language therapists can help children in preserving 
functionality as much as possible. 
Table 3.  Clinical, CSF and MRI Differences Between MS, ADEM, Schilder’s Disease and Devic’s Syndrome 
  MS  ADEM  Schilder’s Disease  Devic’s Syndrome 
Age  > 10 years  < 10 years  5-14 years  20-40 years 
Gender  M> F  M= F  M= F  F> M 
Prior flu  variable very  frequent  _  frequent 
Encephalopathy  rare required  _  _ 
Course  RR, SP,  
PP, PR 
relapsing/monophasic/  
multiphasic 
monophasic-not remitting/ 
remitting/ progressive 
monophasic/ relapsing 
Topography  optic nerve  
cerebellum  
brainstem central  
white matter 
subcortical brainstem  
thalamus 
centrum semiovale  
parieto-occipital  
white matter 
optic nerve/  
spinal cord 
 
Relapses  slight to moderate  moderate  severe  severe 
Brain MRI  small lesions  large, symmetric lesions  large lesions  non specific 
Spinal cord  < 1 segment,   _  _  > 3 segment,  
MRI  marginal    central 
CSF cells  < 50 lymphocytes  > 50 lymphocytes  normal  > 50 PMN 
CSF oligoclonal bands  positive variable negative  negative 
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  Treatments aim to slow the inexorable course of the 
disease. Corticosteroids, such as Methylprednisolone IV, are 
used in high doses and often long courses to control the 
disease. This treatment results in some improvement in the 
majority of patients. Immunoglobulins have been used with 
questionable effects in one case and without effect in two 
patients [60, 62]. 
  Other drugs used were Cyclophosphamide followed by 
Azathioprine in a 12-year old boy, reported to be stable on 
this regime, whereas Azathioprine did not prevent the 
progressive decline in a 12 year old girl [62]. 
  In another patient the use of Ciclophosphamide in 
combination with ACTH was followed by complete reco- 
very. Recent studies about therapy in pediatric patients with 
Schilder’s disease are lacking and the therapy is based on 
both anecdotal reports of the treatment and recommendations 
for MS [60, 61]. 
NEUROMYELITIS OPTICA OR DEVIC’S SYN-
DROME 
  Neuromyelitis optica (NMO) or Devic’s Syndrome is 
another idiopathic inflammatory demyelinating diseases   
of the central nervous system in differential diagnosis with 
MS.  
  It has been long debated whether neuromyelitis optica is 
a variant of MS or a separate disease, because their clinical 
features are similar: optic neuritis, myelitis and inflammatory 
demyelination. Recently Devic’s syndrome has been recog-
nized as a discrete, relapsing, demyelinating disease with 
different clinical, radiological and laboratory findings from 
MS [63]. 
  The first case was described in 1894 by Device and 
Gault, as a disease characterized by optic neuritis and acute 
transverse myelitis. Regarding etiology, the cause of the   
disease is unknown, but various previous or coexisting   
infections (tuberculosis, viral infections), vaccinations and 
systemic autoimmune diseases (LES, Sjogren syndrome, 
rheumatoid arthritis, Hashimoto thyroiditis) have been   
associated with NMO [63, 64]. 
  NMO is the first inflammatory autoimmune demyelinat-
ing disease of the CNS for which a specific antigenic target, 
the astrocytic water channel aquaporin-4 (AQP4), has been 
identified. This protein is located on conglomerated astrocyte 
foot processes, which abut cerebral microvessels of the 
blood-brain barrier. An IgG specific autoantibody for this 
water channel, called NMO-IgG, has been recently discov-
ered and used as a clinically validated serum biomarker for 
the differential diagnosis between NMO and MS. It can be 
detected by an indirect immunofluorescence assay [64, 65]. 
It has been suggested that, in susceptible individuals, an an-
tigenic trigger stimulates production of circulating immuno-
globulin, NMO-IgG, which are able to reach their target an-
tigen (aquaporin-4) through a breach in the blood-brain bar-
rier. The binding of antigen-antibody and the activation of 
complement lead to an inflammatory response. The disrup-
tion of the cellular water transport mechanisms and the in-
flammatory necrosis may explain the radiologic and patho-
logic findings in NMO [64]. NMO is more frequent in 
women than in men (>80% of cases) [66] and affects young 
adults, but throughout the twentieth century children affected 
by NMO were recorded. The average age of onset is 29 years 
for monophasic patients and 39 years for relapsing patients. 
The prevalence and the incidence of this syndrome is un-
known [66, 67]. The attacks of neuritis are more commonly 
unilateral than bilateral, but the presence of bilateral simulta-
neous optic neuritis is a hallmark of NMO and rare in MS. 
The attacks of optic neuritis and myelitis usually occur   
sequentially rather than simultaneously. Complete loss of 
vision, ocular pain with eye movements, incomplete recov-
ery and myelitis with severe symmetric paraparesis or quad-
riparesis, loss of sensation below the site of inflammation 
and bladder and bowel retention or incontinence are typical 
features of NMO. Other symptoms of spinal cord demyelina-
tion consist of paroxysmal tonic spasms and Lermitte’s 
symptom (spinal or limb dysaesthesias caused by neck flex-
ion); cervical myelitis can damage the brainstem, causing 
nausea, vertigo, vomiting, hiccups, diplopia, ataxia or acute 
neurogenic respiratory failure [63, 67, 68]. Today diagnosis 
of NMO requires absolute criteria ( optic neuritis and acute 
myelitis) and at least two out of three supportive criteria ( 
negative brain MRI at disease onset, spinal cord MRI with 
contiguous T2-weighted signal abnormality, extending over 
3 or more vertebral segments and NMO-IgG seropositive 
status) [65]. The natural history of NMO is variable; there 
are two courses of the disease, monophasic or relapsing. 
Most patients (75%) with NMO develop a relapsing course 
with recurrent optic neuritis and myelitis. Optic neuritis can 
be separeted from transverse myelitis by months or years, 
and episodes tend to relapse with significant increasing in 
disability. The monophasic course occurs in about 25 % of 
patients, with concomitant involvement of either unilat-
eral/bilateral optic neuritis and a single episode of transverse 
myelitis. In these patients a longitudinal follow-up over years 
does not reveal new attacks [66, 68]. In regard to treatment, 
it’s necessary to distinguish a therapy for the acute attack 
and a therapy for the relapses. In the first case hospitalization 
is commonly required, particularly when acute ventilatory 
failure occurs. Other manifestations related to myelitis are 
deep vein thrombosis, pulmonary embolism, autonomic dys-
function, deceits ulcers and infections. So the affected pa-
tients often require long term recovery in rehabilitative units 
[66]. Therapy for the acute attacks consists of Methylpredni-
solone IV for 5 days ( 30 mg/kg/day under 30 kg body 
weight to 1 g/day over 30 kg body weight) [9, 66]. In acute 
attacks refractoring to steroids, plasma-exchanges (55 ml/kg 
every other day) and IV Immunoglobulins (0, 4 g/kg once a 
day for 5 days) have also been used and may be somewhat 
helpful to children. Thus plasmapheresis is recommended   
for patients with severe attacks that worsen during corticos-
teroids therapy or do not show improvement [9, 69]. In   
regard to relapsing disease, in a study of seven patients,   
the therapy included a maintenance combination treat- 
ment with Azathioprine (2, 5-3 mg/kg/day) and Prednisone 
(1 mg/kg/day). After two months the prednisone dose was 
gradually reduced until a maintenance dose of 10 mg/day. 
During the follow-up period no attacks were recorded and 
the disability score was improved [66]. Some data suggest 
that Interferon and Glatiramer Acetate are not effective in 
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tiveness of Mycophenolate mofetil, Prednisone, Rituximab, 
Mytoxantrone and Cyclophosphamide in these patients [68, 
70, 71]. 
GUILLAIN BARRÈ SYNDROME 
  Guillain Barrè syndrome (GBS) is an inflammatory auto-
immune disorder affecting the peripheral nervous system in 
which segmental demyelination and conduction block are the 
pathological and electrophysiological correlates of muscle 
weakness [72]. Different subtypes producing the clinical 
picture of GBS have been described including acute inflam-
matory demyelinating polyradiculoneuropathy (AIDP), acute 
motor axonal neuropathy (AMAN), acute motor and sensory 
neuropathy (AMSAN), acute sensory neuronopathy, acute 
pandysautonomia and the Miller- Fisher syndrome [73].  
  GBS incidence is about 0.5-1.5 per 100, 000 people 
younger than 18 years of age. Males are about 1.5 times 
more likely to be affected than female. AIDP is the most 
common GBS subtype in North America, Europe and Aus-
tralia affecting all ages (about 85-90%). In northern China, 
Japan, Asia, Latin America and the developing world axonal 
forms occur more frequently. Atypical cases such as poly-
neuritis cranialis and Miller- Fisher syndrome are much less 
common and reported in 20 of 179 patients (11.2%) [5].  
  Antecedent events such as infections and vaccinations 
occur 1-6 weeks before onset in about 50-82% of children 
[5]. Some of the pathogenic triggers of GBS include viruses 
such as HIV, Epstein-Barr virus, Cytomegalovirus, Hepatitis 
and Varicella. Campylobacter Jejuni infection often with 
diarrhea is the most common identifiable infectious prece-
dent of GBS, particularly with the Miller-Fisher variant. 
Campylobacter jejuni was also found to be responsible   
of summer epidemics of the AMAN form of GBS in   
China [73]. Mycoplasma pneumoniae also remains an impor-
tant antecedent infection responsible for GBS [74]. GBS   
has also been reported following surgery and head trauma 
[75].  
  The disorder is characterized by symmetrical weakness 
which usually begins in the lower extremities and progres-
sively involves the trunk, the upper limbs, and finally the 
bulbar muscles. Classically, both proximal and distal mus-
cles of limbs are involved in AIDP simultaneously [73]. The 
weakness has a gradual onset and reaches its worst within 
four weeks evolving in walking difficulties and later in flac-
cid tetraplegia [76]. Reflexes are usually lost early in the 
illness, although GBS can be associated with retained re-
flexes or even brisk reflexes [76]. Sensory loss, if present, 
usually takes the form of loss of proprioception while loss of 
pain and temperature sensation is usually mild. In fact, pain 
is a common symptom in GBS, presenting as deep aching 
pain which patients compare to the pain from over exercis-
ing. Pain usually affects the weakened muscles but it is often 
localized in the neck and back. In some cases patients com-
plain paresthesias [5].  
  The cranial nerves are often involved, and facial weak-
ness and bulbar palsy are the most common problems, fol-
lowed by eyes movements disorders [76]. Oropharyngeal 
dysphagia and facial weakness interfere with swallowing, 
drooling, and/or maintaining an open airway [78].  
  Respiratory muscle weakness may be severe enough to 
warrant artificial ventilation in about 25% of patients and 
portends a poor prognosis [73]. Dysautonomia occurs in 15% 
of patients manifesting as cardiac arrhythmia, hypertension 
or hypotension, ileus and urinary retention [73].  
  Although the axonal forms of GBS appear similar to 
AIDP, there are important clinical differences. Specifically, 
the axonal forms of GBS exhibit a more rapid and severe 
course, with frequent respiratory involvement and ventilator 
dependence, along with cranial nerves involvement and in-
frequent and mild involvement of the autonomic nervous 
system. The AMAN form is a pure motor syndrome, with 
rapid onset of muscle weakness and absent reflexes, while 
AMSAN is clinically characterized by the presence of both 
motor and sensory deficits [73].  
  Miller-Fisher syndrome is a focal form of GSB consist-
ing of acute external ophthalmoplegia, ataxia and areflexia 
[77]. The course is similar to that of typical GBS and recur-
rences are quite rare [74].  
  Although GBS reaches a nadir at 2 weeks to 4 weeks, 
with most patients recovering from this debilitating illness, 
10% to 20% of patients are left with disabling motor deficits 
and 4% to 15% of patients die by 1 year after onset [5, 73].  
  Prolongation of worsening weakness beyond eight weeks 
excludes the diagnosis of GBS and suggests a diagnosis of 
chronic inflammatory polyneuropathy (CIDP) [74]. Predic-
tive of poorer pediatric outcome are young age, maximum 
disability score at presentation, quadriplegia at day 10, need 
for ventilation support, cranial nerves involvement, and un-
excitable motor nerve conduction [5]. 
  The overall mortality in childhood GBS is estimated to 
be less than 5%. Death may be caused by ventilatory failure, 
cardiac arrhythmias, dysautonomia and pulmonary embolism 
[74].  
  Although GBS is a monophasic illness, about 7% to 16% 
of patients suffer recurrent episodes of worsening after an 
initial improvement [74]. 
  Neurophysiologic studies play a very important role in 
diagnosis, subtype classification, and confirmation of PNS 
involvement [78]. 
  Nerve conduction studies (NCS) rely on abnormalities in 
motor nerves to identify features of demyelination, with sen-
sory nerve conduction studies helping to differentiate differ-
ent forms of axonal GBS, that is AMAN from AMSAN. The 
diagnostic yield of NCS is increased by studying at least 
three sensory and four motor nerves, in addition to F-waves 
and H-reflexes [73]. The classical findings on NCS include 
the presence of a partial motor conduction block, abnormal 
temporal dispersion of motor responses, prolonged distal 
motor and F-wave latencies, and reductions in maximum 
motor conduction velocity [72, 73]. Electromyography 
(EMG) shows evidence of acute denervation of muscle [78]. 
There is no particular best time to do nerve conduction stud-
ies, although they should be done as soon as possible after 
presentation and the studies should be repeated after 1 or 2 
weeks if the initial studies are non-diagnostic or do not allow 
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  CSF examination is essential for GBS diagnosis. Charac-
teristically the CSF protein is raised with <10 mononuclear 
cells/mm3 (albuminocytologic dissociation). In the first days 
of the disease the CSF may be normal [5]. 
  The potential mortality rate (5% in children) necessitates 
hospitalization and regular monitoring of autonomic and 
respiratory function until maximal disability is reached [5]. 
  Patients with slow progression may simply be observed 
for stabilization and spontaneous remission without treat-
ment [5, 79].  
  Intravenous immunoglobulin or plasma exchange (PE) 
are treatment options in severe childhood GBS [80, 81]. Re-
cent American Academy of Neurology practice guidelines 
recommended treatment (with PE or IVIG) for GBS patients 
who were considered immobile [79]. Recovery is hastened 
equally by these two treatment but IVIG is preferred in 
childhood because of less invasiveness and rarer complica-
tions than PE [82, 83].  
  Trials combining IVIG with either plasmapheresis or 
immunoadsorption have failed to demonstrate additional 
benefits when compared to treatment with IVIG alone [5].  
  Experimental evidence shows IVIG may prevent axonal 
degeneration in acute motor axonal neuropathy [5]. A com-
monly recommended protocol is IVIG 0.4g/Kg/day for 5 
consecutive days. However a trial of 50 children found no 
significant difference in outcome when IVIG was given over 
2 days rather than 5 days [84]. The efficacy of IVIG has been 
proved within 2 weeks of symptom onset, so that beyond this 
time it remains uncertain [73, 83]. Moreover there is no evi-
dence that a second course of IVIG is beneficial, but this is 
often used when patients deteriorate or fail to improve 7- 10 
days after a first course of IVIG [83]. 
  PE is generally safe in children who weigh 10 kg or 
more. As a rule, children with sufficiently severe symptoms 
should receive a series of exchanges with a cumulative total 
of approximately 250 ml/kg volume exchange or roughly a 
triple-volume exchange to justify treatment [74]. Trials as-
sessing the efficacy of PE have established that it is effective 
within the first 4 week of illness [73, 83]. 
  There is no definitive role for corticosteroids in the 
treatment of children with GBS at present. Corticosteroids 
alone should not be used in GBS therapy [85]. Combined 
intravenous methylprednisolone and IVIG showed a minor 
synergistic effect however the potential importance of com-
bination treatment with the corticosteroids and IVIG, war-
rants further investigation [86].  
  Studies on adults show that immunoadsorption and CSF 
filtration are effective. CSF filtration possibly removes in-
flammatory mediators such as sodium channel-blocking pen-
tapeptide. Exchange transfusion appears effective in pediat-
ric case reports [5, 87]. However present results are not de-
finitive to recommend the use of these treatment options [5, 
88].  
  There is interest in old and newer drugs which may be 
promising for GBS treatment in the near future. Potential 
therapies include interferon beta-1a, cyclooxygenase-2 in-
hibitors, complement-blocking agents, sodium channel 
blockers (axonal protection) and trophic factors [78, 88]. 
Present evidence is insufficient to recommend the use of 
these therapies [5].  
  Inhibitors of complement activation that prevent the for-
mation of membrane attack complex are highly effective in 
abrogating neuronal and neuromuscular junction damage in 
animal models [89]. 
  Pain is a common feature in GBS in the acute stages. 
Paracetamol, nonsteroidal anti inflammatory drugs, and opi-
ates are useful. Drugs for treatment of neuropathic pain are 
usually of some benefit, including gabapentin, carba-
mazepine, and amitriptyline [83].  
CHRONIC INFLAMMATORY DEMYELINATING 
POLYRADICULONEUROPATHY 
  Children with CIDP present with a subacute onset of 
symmetric proximal and distal weakness that progresses over 
at least 2 months. CIDP is closely related to Guillain Barrè 
syndrome and it is considered the chronic counterpart of the 
acute disease. Its symptoms are also similar to progressive 
inflammatory neuropathy [74]. The two mandatory clinical 
research criteria for the diagnosis of CIDP include the fol-
lowing: (1) progressive or relapsing motor and sensory dys-
function of more than one limb and (2) hyporeflexia or are-
flexia, which usually involves all four limbs [90].  
  The estimated prevalence is 0.48 per 100, 000 children 
with a male preponderance and antecedent illnesses or vac-
cinations occur in approximately half of patients [91]. Onset 
occurs from birth, with most childhood cases occurring be-
fore 10 years of age [5]. 
  The clinical manifestations of CIDP at the time of refer-
ral and at a more chronic phase of the illness may be ex-
tremely variable [91]. Children present mainly with progres-
sive weakness and loss of neurological function primarily in 
the legs and arms. Proximal and distal limbs are commonly 
affected in roughly symmetrical pattern [5]. Some patients 
present with a progressive sensory ataxia; in other patients 
motor deficits predominate [92]. Only a minority of children 
present with sensory symptoms such as tingling and numb-
ness of hands and feet; however, sensory findings occur in 
most children [5]. Cranial nerve and respiratory muscle in-
volvement are uncommon, although both may occur. Auto-
nomic system dysfunction can appear; in this case, the pa-
tient would complain of orthostatic dizziness, problems with 
bowel and bladder functions, and cardiac problems [88]. 
Presentation may be monophasic with complete recovery, 
relapsing remitting, slow-progressive, or stepwise progres-
sive, and should be distinguished from acute immune neu-
ropathies and hereditary motor and sensory neuropathies [5]. 
  The diagnosis is made clinically with the support of elec-
trophysiological studies which show evidence of a motor and 
sensory demyelinating polyradiculoneuropathy, often patchy 
and often with evidence of conduction block or temporal 
dispersion that distinguish CIDP from hereditary demyelinat-
ing neuropathies [89]. The diagnosis is supported by the 
presence of raised CSF protein without cells, thickened 
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spine, a positive response to immunomodulatory treatment or 
unequivocal quantitative biopsy features consistent with de-
myelination and remyelination with or without actively visu-
alized macrophage-associated demyelination [6, 89]. 
  There have been no randomized trials regarding first-line 
treatment in pediatric patients, which is in part related to the 
rarity of this disease. Therefore, treatment for pediatric pa-
tients has paralleled the treatment used in adults, included 
intravenous immunoglobulin, corticosteroids, PE, or other 
immunosuppressive medications [93]. When these treat-
ments were compared no significant difference in efficacy 
was found, so the initial treatment is often chosen on the 
basis of its cost, availability, and side effects [89, 94]. 
  Steroids induced short-term improvement in 71-100% of 
children in small series. The best regimen in children is not 
known. Initially 1-2 mg/kg/day oral prednisone (maximum 
60-80mg) usually results in improvement within 1- 4 weeks. 
Slow tapering is begun after significant improvement, but 
not before 4-6 weeks. Relapses are frequent with rapid taper-
ing; therefore, a slow reduction by 5mg every 2 weeks is 
recommended after a clinical response. Deterioration may 
occur within days of starting steroids. Intermittent pulse in-
travenous methylprednisolone may have less corticosteroid 
side effects over the longer-term than oral corticosteroids [5]. 
Adverse effects of prednisone seen in pediatric patients in-
clude increased appetite, emotional lability, weight gain, 
cushingnoid features, hypertension, and growth retardation. 
Other adverse effects are well known to occur with pro-
longed corticosteroid treatment, including increased suscep-
tibility to infection, increased blood glucose, osteoporosis, 
development of cataracts. Children treated chronically with 
corticosteroids may have persistent weight gain even after 
the cessation of therapy [95]. 
  IVIG (at a dose of 0.4 mg/kg/day for 5 consecutive days) 
have showed good efficacy in 50-88% of pediatric CIDP 
cases, improving disability for 2-12 weeks and may be used 
as initial therapy because of paucity of side effects. A pro-
portion of patients need recurrent treatments (months-years) 
to maintain improvement [96].  
  Adverse effects of IVIG in pediatric patients are mild and 
without long-term consequences. They include headaches, 
myalgias, and malaise. They can be mitigated with pretreat-
ment and treatment during the infusion with analgesics, non-
steroidal anti-inflammatory drugs, and antihistamines, as 
well as by maintaining adequate hydration and decreasing 
the infusion rat [95].  
  A new development is the use of subcutaneous immuno-
globulin (ScIg) but its efficacy has not been tested in pediat-
ric patients. Two adult CIDP patients treated with ScIg have 
been reported. Application of ScIg was well tolerated, easy 
to manage, and led to stabilization of the disease course [96]. 
  PE showed good short-term improvement in 50-100% of 
children in small CIDP series [5]. Plasmapheresis is less of-
ten used in children because it requires the installation of 
central catheters, with potential infectious and thrombotic 
complications, as well as hemodynamic complications of the 
treatment itself [93]. Two to three exchanges for week may 
be given for 6-10 treatments or until improvement, and then 
frequency tapered over several months. PE should be re-
duced gradually and occasionally used with immunosuppres-
sive due to possible rebound worsening. Patients refractory 
to immunosuppressive/IVIG may improve when PE is fol-
lowed immediately by IVIG [5].  
  Only a minority of studies report treatment outcomes 
with immune-modulating drugs in childhood chronic in-
flammatory demyelinating polyneuropathy. Treatments used 
include azathioprine, methotrexate, cyclosporine and cyclo-
phosphamide [93].  
  In childhood, there is the most experience with azathio-
prine, although it is still limited. Some authors reported us-
ing azathioprine usually as a second-line agent when corti-
costeroid had failed or as a steroid-sparing agent [97]. The 
efficacy of azathioprine in childhood is still unclear. A fa-
vorable response had been reported in some patients while, 
in other series of childhood CIDP patients, azathioprine ther-
apy failed [98, 99]. Side effects include nausea, vomiting, 
diarrhea, rash, leucopenia, altered liver function, infection 
and risk of neoplasia. Ten percent of the population is het-
erozygous and 0.3% homozygous for inability to metabolize 
azathioprine, and decreased serum thiopurine methyltrans-
ferase levels identify these patients [5, 89, 96, 98, 100]. 
  Methotrexate showed good response in children refrac-
tory to prednisolone, IVIG, azathioprine and cyclosporine. 
Side effects are hematological, nephrotoxic, hepatic, gastro-
intestinal, pulmonary and ocular [5, 99]. Cyclosporine and 
other calcineurin inhibitors, including tacrolimus, block the 
activity of the phosphatase calcineurin necessary to activa-
tion and proliferation of T-cell subsets. Cyclosporine 
(5mg/day) has been beneficial in some patients with CIDP. 
Clinical response was characterized by either decreased fre-
quency of recurrent weakness or normalized motor function. 
Side effects include nephrotoxicity, electrolyte disturbances, 
hypertension, nausea, edema, neurotoxicity, and hirsutism [5, 
101, 102]. 
  Cyclophosphamide was used in one patient (at a dose of 
4 mg/kg per day) for a period of 9 months, with improve-
ment apparent within 1 month of onset of therapy and sus-
tained after cessation [103].  
  Adults and childhood with CIDP have shown improve-
ment with interferon ,  in several small studies [5, 96, 97, 
101, 103]. Side effects include flulike symptoms, hypothy-
roidism, and hepatic toxicity [101]. In children with MS re-
sponded remarkably to INF-, the development of CIDP has 
been described and one could consider the possibility that 
IFN treatment somehow contributed to the development of 
CIDP [104]. Other agents such as mycophenolate mofetil, 
etanercept (tumour necrosis factor alpha antagonist) and tac-
rolimus (FK-506) are potential treatments for CIDP but the 
efficacy and safety in children has not been reported [5, 
105]. 
  The future of treatment for CIDP may lie in more spe-
cific biological agents targeted at key points in the patho-
physiological pathway. Rituximab is an agent on which at-
tention is focused for future RCTs [89]. Only one paediatric 
report of monoclonal antibody use showed persistent re-
lapses on Rituximab (anti- CD20) [5, 93]. Alemtuzumab 146    Current Neuropharmacology, 2010, Vol. 8, No. 2  Spalice et al. 
(anti-CD52) achieved remission in a 19-year-old unrespon-
sive to IVIG, prednisolone and azathioprine [106]. Side   
effects include hypotension, fever, chills, rash, hypogamma-
globulinemia and immunesuppression [5]. 
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